Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12639681 | 0.99 | KMT2A (0.46) | KMT2AMEN1EPHX2TSHRKDM4E | |
| SCHEMBL12639608 | 0.94 | EPHX2 (0.46) | KMT2AMEN1EPHX2TSHRKDM4E | |
| SCHEMBL12639539 | 0.93 | KMT2A (0.48) | KMT2AMEN1EPHX2TSHRKDM4E | |
| SCHEMBL12639506 | 0.93 | LMNA (0.47) | KMT2AMEN1EPHX2TSHRKDM4E | |
| SCHEMBL12639503 | 0.92 | KMT2A (0.45) | KMT2AMEN1EPHX2TSHRKDM4E | |
| SCHEMBL12639558 | 0.92 | KMT2A (0.44) | KMT2AMEN1EPHX2TSHRKDM4E | |
| SCHEMBL12639536 | 0.92 | KMT2A (0.46) | KMT2AMEN1EPHX2TSHRKDM4E | |
| SCHEMBL12639533 | 0.91 | POLB (0.46) | KMT2AMEN1EPHX2TSHRKDM4E | |
| SCHEMBL12639554 | 0.91 | EPHX2 (0.43) | KMT2AMEN1EPHX2TSHRKDM4E | |
| SCHEMBL12639584 | 0.90 | KMT2A (0.43) | KMT2AMEN1EPHX2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| WO-2009150248-A1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | CYTOMICS SYSTEMS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | VHL, CYP11B2, SLC10A1 | KMT2A 3789/4885MEN1 70/4885EPHX2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.